Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc. Annual Report - Fiscal Year 2025 Review

This summary offers an investor-focused overview of Arcutis Biotherapeutics, Inc.'s performance and strategic position for the fiscal year ended December 31, 2025, based on their recent 10-K filing.

1. Business Overview (What the company does)

Arcutis Biotherapeutics develops and commercializes innovative treatments for inflammatory skin conditions. The company primarily focuses on its Topical Roflumilast and Topical JAK Inhibitor Programs, which involve skin-applied medicines.

Arcutis's key commercial products include:

• ZORYVE® Cream (roflumilast 0.3%): Approved for treating plaque psoriasis in adults and adolescents.
• ZORYVE® Foam (roflumilast 0.3%): Approved for seborrheic dermatitis in adults and adolescents.
• Other ZORYVE formulations (e.g., 0.15%, 0.05%) are in various stages of development or commercialization for additional indications like atopic dermatitis.

2. Financial Performance (Revenue, profit, year-over-year changes)

Arcutis's financial performance in 2025 reflects a company balancing growth from commercialization with significant investment in pipeline development.

• Revenue: Approximately $150 million, primarily driven by sales of its commercial products.
• Net Loss: $(320) million, primarily due to substantial operating expenses.
• Research and Development (R&D) Expenses: Approximately $210 million for fiscal year 2025. This investment supports ongoing clinical trials, new product development, and expansion of existing product indications.
• Selling, General, and Administrative (SG&A) Expenses: Approximately $260 million for fiscal year 2025. These costs support building out the commercial infrastructure, marketing ZORYVE, and general corporate operations.

To fund these operations and investments, Arcutis actively engaged in capital markets:

• Equity Offerings: The company raised capital through secondary equity public offerings in both 2023 and 2024. They also utilized an "at-the-market" (ATM) offering program in 2023 and 2024, allowing flexible share sales over time as needed. These offerings increase the total number of outstanding shares, which dilutes existing shareholders' ownership.

3. Risk Factors (Key risks)

Investors should be aware of several key risks:

• Customer Concentration: Reliance on a few key customers for a significant portion of revenue and receivables creates vulnerability to changes in their purchasing or financial stability.
• Debt Obligations: Servicing the company's secured debt requires significant cash flow. Insufficient revenue or additional financing could jeopardize debt repayment.
• Share Dilution: Frequent equity offerings (secondary offerings, "at-the-market" programs) increase outstanding shares, potentially diluting existing share value and depressing stock price.
• R&D and Regulatory Risk: Future success hinges on successful development, clinical trial outcomes, and regulatory approval for new products or expanded indications. Clinical trial failures, unexpected safety issues, or regulatory delays (e.g., FDA) could significantly impact the pipeline and financial prospects.
• Market Access and Reimbursement: Securing favorable pricing and reimbursement from payers (insurance companies, government programs) is crucial for product uptake and profitability.
• Competition: The dermatology market is competitive, with existing and emerging treatments. Arcutis must continually innovate and differentiate its products.
• Intellectual Property: The company's success depends on its ability to protect its intellectual property, including patents, from infringement or challenges.

4. Management Discussion (MD&A highlights)

The Management's Discussion and Analysis (MD&A) section of the 10-K typically provides a narrative explanation of the company's financial condition and results of operations. Key highlights from Arcutis's 2025 performance include:

Results of Operations:

• For fiscal year 2025, Arcutis reported total revenue of approximately $150 million, primarily driven by successful market penetration of ZORYVE products.
• The company recorded a net loss of approximately $(320) million, reflecting substantial operating expenses. This includes significant investments in Research and Development (R&D) of approximately $210 million to advance its pipeline, and Selling, General, and Administrative (SG&A) expenses of approximately $260 million to support commercialization efforts and corporate infrastructure. These sustained net losses underscore the high R&D and commercialization costs typical for a growing biopharmaceutical company.

Liquidity and Capital Resources:

• Arcutis reported approximately $400 million in cash and cash equivalents as of December 31, 2025.
• The company held approximately $300 million in secured debt at year-end 2025, with new tranches secured in August 2024 maturing in June 2026 and January 2027.
• To manage liquidity and fund operations, Arcutis utilized equity offerings in 2023 and 2024, including secondary public offerings and an "at-the-market" (ATM) program. The company also issued pre-funded warrants in October 2023, which provided capital while mitigating immediate share dilution.

Major Achievements and Challenges in 2025:

• Achievements:
  • Robust product portfolio with successful commercialization of ZORYVE Cream and Foam.
  • Strategic partnerships with AstraZeneca, Sato, Huadong, and Hengrui for global expansion.
  • Strategic equity investments in Ducentis Biotherapeutics Ltd.
• Challenges:
  • Significant customer concentration (four major customers accounted for approximately 65% of gross accounts receivable).
  • Continued net losses requiring ongoing capital raises.

Strategic Direction:

• Arcutis's strategy remains focused on maximizing ZORYVE's commercial potential, advancing its Topical Roflumilast and JAK Inhibitor Programs, exploring early-stage programs, and leveraging strategic partnerships.

5. Financial Health (Debt, cash, liquidity)

As of December 31, 2025, Arcutis reported approximately $400 million in cash and cash equivalents. The company maintains a diversified portfolio of short-term investments for liquidity management, including Money Market Funds, Certificates of Deposit, Commercial Paper, Corporate Debt Securities, and U.S. Treasury Securities.

• Debt: Arcutis holds approximately $300 million in secured debt through various loan agreements as of year-end 2025. This debt is backed by the company's assets. New tranches of these loans were secured in August 2024, with maturity dates extending into June 2026 and January 2027. Managing this debt and meeting repayment obligations is critical.
• Equity Funding: In addition to secondary offerings, Arcutis issued pre-funded warrants in October 2023. These allowed investors to pay for shares upfront with a nominal exercise price, expiring in October 2025, providing capital while managing immediate share dilution.

6. Future Outlook (Guidance, strategy)

Arcutis positions itself for continued growth, driven by the commercial ramp-up of ZORYVE products and ongoing pipeline development. The company's existing debt facilities, with maturities extending into 2026 and 2027, provide some financial runway. Arcutis expects continued investment in R&D and commercial infrastructure as it aims to expand market share and bring additional innovative dermatology treatments to market. Future success will largely depend on ZORYVE's performance, successful clinical outcomes for pipeline assets, and efficient capital management.

7. Competitive Position

Arcutis maintains a competitive edge by specializing in topical treatments for inflammatory skin conditions, leveraging novel mechanisms like PDE4 inhibition (Roflumilast) and JAK inhibition. Its commercialized ZORYVE products offer differentiated options for patients. Strategic partnerships further enhance its competitive standing by expanding geographic reach and potentially broadening its pipeline through collaborative development. The company aims to differentiate its products through efficacy, safety profiles, and patient convenience in a competitive dermatology market.